Company Overview and News
Every now and then the elephant in the run stomps and makes a lot of noise. Investors had better pay attention because the problem that everyone hoped would never be voiced now makes the front pages followed by potentially more stock impact.
Good morning and welcome to the Goodrich Petroleum Year-End 2017 Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there'll be an opportunity to ask questions. [Operator Instructions] Please also note that today's event is being recorded.
In Part 1 of this article, I discussed my own views on certain macroeconomic factors that investors should follow in 2018, including global and U.S production and pricing levels.
US distillate inventories fell by 3.8 MMbbls (million barrels) or 2.7% to 139.2 MMbbls on January 5–12, 2018. The inventories also fell by 29.9 MMbbls or 18% from a year ago.
India is the world’s third-largest crude oil consumer. Its oil imports hit a record in 2017. India’s crude oil imports rose 1.8% to 4.3 MMbpd (million barrels per day) in 2017, according to Reuters. An increase in domestic demand led to the rise in refinery demand, which caused the rise in crude oil imports. India’s crude oil refining capacity increased to 5 MMbpd in 2H17. Any rise in crude oil imports from India is bullish for oil (UWT) (DWT) prices.
The EIA will release its weekly crude oil inventory report on January 18, 2018. OPEC will release its monthly oil market report on the same day. The IEA will release its oil market report on January 19, 2018.
US distillate inventories rose by 4.2 MMbbls (million barrels) to 143.1 MMbbls between December 29, 2017, and January 5, 2018, according to the EIA. Inventories rose 3.1% week-over-week but fell by 26.9 MMbbls or 16% YoY.
Russia’s crude oil production averaged 10.98 MMbpd (million barrels per day) in 2017, according to Russia’s Ministry of Energy. Production rose 0.1% year-over-year in 2017—a 30-year high. Production rose for the ninth consecutive year. Production rose 0.1% to 10.95 MMbpd in December 2017—compared to the previous month. Russia’s crude oil production increased despite ongoing output cuts.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET